Evidence map›Paper›PMID 42621046›Full record

ArticleInternational journal of clinical and experimental pathology2026

PDGFRA mediates the PI3K/AKT signaling pathway to regulate the growth and phenotype of GCTB tumor cells.

Tiantian Zhang, Wanjing Song, Zhengqing Yan, Zhonghua Zhao, Zhongqing Chen, Feng Tang, Kanda Gao, Feiyan Chen, Hongguang Zhu, Shuyang Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical and experimental pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tiantian ZhangDepartment of Pathology, School of Basic Medicine, Fudan University Shanghai, China.
Wanjing SongDepartment of Pathology, School of Basic Medicine, Fudan University Shanghai, China.
Zhengqing YanDepartment of Pathology, School of Basic Medicine, Fudan University Shanghai, China.
Zhonghua ZhaoDepartment of Pathology, School of Basic Medicine, Fudan University Shanghai, China.
Zhongqing ChenDepartment of Pathology, Huashan Hospital Affiliated to Fudan University Shanghai, China.
Feng TangDepartment of Pathology, Huashan Hospital Affiliated to Fudan University Shanghai, China.
Kanda GaoDepartment of Orthopedics, Huashan Hospital Affiliated to Fudan University Shanghai, China.
Feiyan ChenDepartment of Orthopedics, Huashan Hospital Affiliated to Fudan University Shanghai, China.
Hongguang ZhuDepartment of Pathology, School of Basic Medicine, Fudan University Shanghai, China.
Shuyang WangDepartment of Pathology, School of Basic Medicine, Fudan University Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe nature of true neoplastic cells of giant cell tumor of bone (GCTB) remains unverified. As the effect of denosumab on true neoplastic cells needs to be clarified, direct targeting of these cells remains unclear.

methodsIn this study, we obtained 32 formalin-fixed paraffin-embedded (FFPE) GCTB tissue blocks, performing H&E staining and immunohistochemistry staining of CD68. Multinucleated giant cells, monocytes, and CD68-negative mononuclear spindle cells were accurately captured by laser capture microdissection. The DNA of these cells was extracted, digested with

resultsIn

conclusionCD68 negative mononuclear spindle cells are the true neoplastic cells of GCTB. PDGFRA inhibition may be a novel targeted therapy for GCTB.

Indexed as

clonality analysisGiant cell tumor of bonePDGFRA

Identifiers

PMID42621046
PMCPMC13485989

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.